CERO THERAPEUTICS HOLDINGS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CERO THERAPEUTICS HOLDINGS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($19.92M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2024 | ($7.73M) | Apr 15, 2025 |
| FY2024 | Feb 13, 2024 | ($572.2K) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($7.29M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($667.7K) | Apr 2, 2024 |
| FY2022 | Dec 31, 2021 | ($315.5K) | Mar 24, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($15.30M) | Apr 15, 2025 |
| FY2024 | Feb 13, 2024 | ($897.1K) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | ($7.68M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($2.91M) | Apr 2, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $6.32M | Apr 15, 2025 |
| FY2024 | Feb 13, 2024 | $764.2K | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | $5.29M | Apr 15, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($16.10M) | Apr 15, 2026 |
| FY2023 | Dec 31, 2023 | ($1.52M) | Apr 2, 2024 |
| FY2023 | Dec 31, 2022 | ($1.09M) | Apr 2, 2024 |
| FY2022 | Dec 31, 2021 | ($697.1K) | Mar 24, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.64M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $6.21M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $5.13M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $42.37M | Apr 2, 2024 |
| FY2022 | Dec 31, 2021 | $180.08M | Mar 24, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.09M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $8.10M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $5.08M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $39.90M | Apr 2, 2024 |
| FY2022 | Dec 31, 2021 | $9.25M | Mar 24, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.45M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($1.89M) | Apr 15, 2026 |
| FY2025 | Feb 14, 2024 | ($2.35M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($42.06M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($11.00M) | Apr 2, 2024 |
| FY2023 | Dec 31, 2021 | ($7.67M) | Apr 2, 2024 |
| FY2022 | Jun 7, 2021 | $0 | Mar 24, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($90.84M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($70.92M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($43.09M) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($11.00M) | Apr 2, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $96.9K | Apr 2, 2024 |
| FY2023 | Dec 31, 2022 | $475.9K | Apr 2, 2024 |
| FY2022 | Dec 31, 2021 | $1.10M | Mar 24, 2023 |
| FY2021 | Jun 7, 2021 | $0 | Mar 24, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (18) | Apr 15, 2025 |
| FY2024 | Feb 13, 2024 | (97) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | (1,248) | Apr 15, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (18) | Apr 15, 2025 |
| FY2024 | Feb 13, 2024 | (97) | Apr 15, 2025 |
| FY2024 | Dec 31, 2023 | (1,248) | Apr 15, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | 5,845 | Apr 15, 2025 |